Boost Your Productivity!Translate documents (Ms-Word, Ms-Excel, ...) faster and better thanks to artificial intelligence!
https://pro.wordscope.com
https://blog. wordscope .com
Système d’information de cardiologie
Système d’information de chevet
Système d’information de la banque du sang
Système d’information de soins d’urgence
Système d’information de soins à domicile

Traduction de «risk information » (Français → Néerlandais) :

TERMINOLOGIE
voir aussi les traductions en contexte ci-dessous






informer les professionnels de la santé sur les résultats des tests

informeren van zorgverlener over testresultaat


informer les professionnels de la santé sur les résultats des tests de gaz sanguins artériels

informeren van zorgverlener over resultaat van arteriële bloedgasanalyse


logiciel d’application de système d’information financière de l’hôpital

applicatiesoftware voor informatiesysteem voor financiële administratie van een ziekenhuis


logiciel d’application de système d’information de chevet

applicatiesoftware voor informatiesysteem aan bed


informer les professionnels de la santé sur la présence d'un implant

informeren van zorgverlener over aanwezigheid van implantaat




TRADUCTIONS EN CONTEXTE
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or ...[+++]

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.


This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or ...[+++]

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.


Sur le site Internet de l’inspection du travail de Suède, vous trouverez plus d’information sur la campagne en anglais: Campaign on psychosocial risks at work in 2012.

Op de website van de Zweedse arbeidsinspectie vindt u meer informatie in het Engels over de campagne: Campaign on psychosocial risks at work in 2012.


This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.


For more results, go to https://pro.wordscope.com to translate your documents with Wordscope Pro!
sexe, champ 20: lieu avant l’admission, champ 21: type d’admission, champ 22: renvoi par, champ 23: destination, champ 24: type de sortie; numéro CTI, année d’enregistrement, semestre d’enregistrement, numéro de séjour, variable dérivée APR-DRG 15.0, variable dérivée Risk of mortality, variable dérivée Severity of illness; fichier ‘diagnostic’: champ 6: diagnostic et informations urgences, champ 7: code diagnostic principal / secondaire et informations urgences.

geslacht, Veld 20: plaats voor opname, Veld 21: type opname, Veld 22: verwezen door, Veld 23: bestemming, Veld 24: type ontslag; CIVnummer, Registratiejaar, Registratiesemester, Verblijfsnummer, Afgeleide variabele APR- DRG 15.0, Afgeleide variabele Risk of mortality, Afgeleide variabele Severity of illness; Bestand ‘diagnose’: Veld 6: diagnose en info spoed; Veld 7: code hoofd-/nevendiagnose en info spoed.


This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases.

DISCLOSURE NOTICE: The information contained in this release is as of December 13, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.


Le réseau " EFSA scientific network for risk assessment in plant health" se charge quant à lui de l'échange d'informations et de la coordination de toutes les activités liées à l'analyse de risques pour la santé des végétaux dans l'UE.

Het ‘EFSA scientific network for risk assessment in plant health’ zorgt dan weer voor de informatie-uitwisseling en coördinatie van alle werkzaamheden rond risicoanalyse voor de plantengezondheid binnen de EU.


This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.

DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.


Rapport d’enquête du ‘Health & Safety Executive’ (HSE) britannique (en anglais): RR962 - Survey of noise emission and risk information supplied with a range of work machinery

Onderzoeksrapport van het Britse ‘Health & Safety Executive’ (HSE) (in het Engels): RR962 - Survey of noise emission and risk information supplied with a range of work machinery




datacenter (12): www.wordscope.be (v4.0.br)

risk information ->

Date index: 2023-01-08
w